Re: Platelet-rich Plasma for the Treatment of Erectile Dysfunction: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial
Research output: Contribution to journal › Comment/debate › Research › peer-review
Masterson et al. [1] have presented the third randomized controlled trial (RCT) on platelet-rich-plasma (PRP) and erectile dysfunction (ED). Men with vasculogenic ED were assigned to intracavernosal PRP injections (n = 28) or placebo (n = 33). No significant differences were noted between the arms: 58.3%, 41.7%, and 60% of the PRP group, and 53.6%, 52%, and 41.7% of the placebo group met the minimal clinically important difference (MCID) for the International Index of Erectile Function-Erectile Function (IIEF-EF) scale at 1, 3, and 6 mo, respectively. The findings are in contrast to two previous RCTs and the inconsistencies necessitate a closer examination of the studies.
Original language | English |
---|---|
Journal | European Urology |
Volume | 85 |
Issue number | 1 |
Pages (from-to) | 93 |
Number of pages | 1 |
ISSN | 0302-2838 |
DOIs |
|
Publication status | Published - 2024 |
ID: 382432574